Objective:To apply Zhilong Huoxue Tongyu Capsule in the treatment of acute ischemic stroke with syndrome of wind-phlegm stasis

and to investigate its impact on nerve function and levels of tumor necrosis factor（TNF）-α

interleukin（IL）-1β

and IL-6 in peripheral blood. Methods:Sixty acute ischemic stroke patients with syndrome of wind-phlegm stasis were randomly and equally divided into Zhilong group（basic treatment + Zhilong Huoxue Tongyu Capsule at a dose of 1.6 g

three times a day） and non-Zhilong group（basic treatment）. The course of treatment was 1 week. The levels of TNF-α

IL-1β

and IL-6 in peripheral blood

the National Institutes of Health Stroke Scale（NIHSS） score

and Barthel Index（BI） score were determined on days 1

3

and 7. Results:From day 1 to day 7

the levels of TNF-α

IL-1β

and IL-6 in peripheral blood gradually decreased in patients with stroke. The reduction was significantly greater in the Zhilong group than in the non-Zhilong group（P < 0.05）. After treatment

both groups had significantly reduced NIHSS scores and significantly increased BI scores（P < 0.05）. On day 7

the Zhilong group had a significantly lower NIHSS score and a significantly higher BI score than the non-Zhilong group（P < 0.05）. Conclusion:Zhilong Huoxue Tongyu Capsule can decrease levels of TNF-α

IL-1β

and IL-6 in peripheral blood

reduce NIHSS score

and increase BI score in stroke patients. It can reduce the immune inflammatory response

protect the brain tissue

promote the recovery of nerve function

improve the activities of daily living

and improve the prognosis of patients.